Antonella De Luca

List of Publications by Year
in descending order

93 papers	8,132 citations	101384 36 h-index	53109 85 g-index
96 all docs	96 docs citations	96 times ranked	11566 citing authors

#	Article	IF	Citations
1	Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006, 366, 2-16.	1.0	1,744
2	Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. New England Journal of Medicine, 2009, 360, 679-691.	13.9	976
3	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opinion on Therapeutic Targets, 2012, 16, S17-S27.	1.5	580
4	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature Reviews Clinical Oncology, 2009, 6, 519-527.	12.5	391
5	The role of the EGFR signaling in tumor microenvironment. Journal of Cellular Physiology, 2008, 214, 559-567.	2.0	323
6	Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.. Endocrine-Related Cancer, 2003, 10, 1-21.	1.6	279
7	The ErbB Receptors and their Ligands in Cancer: An Overview. Current Drug Targets, 2005, 6, 243-257.	1.0	257
8	Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-Related Cancer, 2005, 12, 721-747.	1.6	242
9	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Annals of Oncology, 2002, 13, 65-72.	0.6	240
10	VEGF as a potential target in lung cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 959-966.	1.5	159
11	The role of EGF-related peptides in tumor growth. Frontiers in Bioscience - Landmark, 2001, 6, d685.	3.0	141
12	Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells. Molecular and Cellular Biology, 2002, 22, 2586-2597.	1.1	139
13	Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. Journal of Clinical Investigation, 2003, 112, 575-587.	3.9	136
14	The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. Journal of Cellular Physiology, 2006, 207, 420-427.	2.0	127
15	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action?. Journal of Cellular Physiology, 2003, 194, 13-19.	2.0	124
16	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treatment Reviews, 2018, 70, 1-8.	3.4	116
17	Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocrine-Related Cancer, 2005, 12, 471-482.	1.6	93
18	Mesenchymal stem cellâ€derived interleukinâ€6 and vascular endothelial growth factor promote breast cancer cell migration. Journal of Cellular Biochemistry, 2012, 113, 3363-3370.	1.2	92

#	Article	IF	Citations
19	Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. Journal of Cellular Physiology, 2011, 226, 2131-2138.	2.0	91
20	Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene, 2000, 19, 5863-5871.	2.6	88
21	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncology, 2015, 11, 1611-1623.	1.1	82
22	Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer. Clinical Cancer Research, 2006, 12, 5158-5164.	3.2	79
23	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget, 2016, 7, 66595-66605.	0.8	78
24	Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Annals of Oncology, 2012, 23, 597-604.	0.6	67
25	FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention. International Journal of Molecular Sciences, 2020, 21, 6856.	1.8	67
26	Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities. Journal of Cellular Biochemistry, 2013, 114, 514-524.	1.2	66
27	Target-based therapies in breast cancer: current status and future perspectives. Endocrine-Related Cancer, 2009, 16, 675-702.	1.6	62
28	Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. Journal of Cellular Physiology, 2004, 198, 31-39.	2.0	61
29	Prognostic value of circulating tumor cellsâ€™ reduction in patients with extensive small-cell lung cancer. Lung Cancer, 2014, 85, 314-319.	0.9	56
30	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers, 2019, 11, 341.	1.7	52
31	Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. Current Drug Targets, 2010, 11, 851-864.	1.0	46
32	Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Translational Lung Cancer Research, 2017, 6, 486-498.	1.3	43
33	Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Research and Treatment, 2008, 112, 25-33.	1.1	40
34	Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. Cell Cycle, 2014, 13, 148-156.	1.3	40
35	EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. Journal of Cellular Biochemistry, 2015, 116, 2778-2785.	1.2	40
36	EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. , 1999, 80, 589-594.		39

#	Article	IF	Citations
37	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Research and Treatment, 2010, 123, 387-396.	1.1	39
38	Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells. Journal of Cellular Physiology, 2016, 231, 1514-1521.	2.0	39
39	Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. , 1997, 73, 277-282.		35
40	Quercetinâ€3â€methyl ether inhibits lapatinibâ€sensitive and â€resistant breast cancer cell growth by inducing G₂/M arrest and apoptosis. Molecular Carcinogenesis, 2013, 52, 134-143.	1.3	35
41	Expression and functional role of CRIPTO-1 in cutaneous melanoma. British Journal of Cancer, 2011, 105, 1030-1038.	2.9	34
42	Gefitinib inhibits the crossâ€talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. Journal of Cellular Biochemistry, 2013, 114, 1135-1144.	1.2	34
43	EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. Annals of Oncology, 2000, 11, 319-326.	0.6	33
44	A â€œliveâ€•biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. Lung Cancer, 2009, 65, 123-125.	0.9	32
45	Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology. BioMed Research International, 2013, 2013, 1-9.	0.9	32
46	Targeting the EGFR T790M mutation in non-small-cell lung cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 159-165.	1.5	28
47	Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers, 2019, 11, 859.	1.7	27
48	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics, 2015, 16, 1135-1148.	0.6	26
49	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. Cancers, 2020, 12, 2914.	1.7	26
50	Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. Cancers, 2020, 12, 3804.	1.7	26
51	Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.. Oncology Reports, 1999, 6, 1105-9.	1.2	26
52	FGFR-targeted therapeutics for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2017, 26, 303-311.	1.9	25
53	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. Frontiers in Bioscience - Landmark, 2005, 10, 2611.	3.0	22
54	RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells. Oncotarget, 2018, 9, 17543-17553.	0.8	22

#	Article	IF	Citations
55	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). Oncotarget, 2018, 9, 17554-17563.	0.8	21
56	Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. Journal of Cellular Physiology, 2002, 190, 74-82.	2.0	20
57	Prognostic Applications of Gene Expression Signatures in Breast Cancer. Oncology, 2009, 77, 2-8.	0.9	20
58	Transforming growth factor Î±, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. International Journal of Oncology, 2002, 21, 941.	1.4	19
59	The prognostic role of circulating tumor cells in lung cancer. Expert Review of Anticancer Therapy, 2016, 16, 859-867.	1.1	16
60	Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 891-900.	1.5	16
61	RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells. Oncotarget, 2014, 5, 10518-10528.	0.8	16
62	AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Research and Treatment, 2007, 102, 275-282.	1.1	15
63	Structureâ€“fluctuationâ€“function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 410-425.	1.1	14
64	Pharmacokinetic evaluation of zoledronic acid. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 911-918.	1.5	13
65	The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells. Expert Review of Molecular Diagnostics, 2019, 19, 683-694.	1.5	13
66	Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1177-1185.	1.5	11
67	Small Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: An Overview. Journal of Chemotherapy, 2004, 16, 36-40.	0.7	10
68	Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?. Annals of Oncology, 2005, 16, 1709.	0.6	10
69	Vandetanib as a potential treatment for breast cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1295-1303.	1.9	10
70	Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. Translational Lung Cancer Research, 2020, 9, 61-70.	1.3	10
71	Pharmacokinetic evaluation of capecitabine in breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 225-235.	1.5	9
72	CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. International Journal of Oncology, 2004, 25, 1013-20.	1.4	9

#	Article	IF	Citations
73	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 1653-1665.	1.3	8
74	Extracellular matrix proteins as circulating biomarkers for the diagnosis of non-small cell lung cancer patients. Journal of Thoracic Disease, 2019, 11, S1252-S1256.	0.6	7
75	Promising Role of Circulating Tumor Cells in the Management of SCLC. Cancers, 2021, 13, 2029.	1.7	7
76	Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?. Journal of Clinical Oncology, 2007, 25, 5836-5837.	0.8	6
77	Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. Expert Review of Anticancer Therapy, 2011, 11, 299-307.	1.1	5
78	Modulation of Epidermal Growth Factor Receptorâ€“Positive Circulating Tumor Cells by Chemotherapy in Nonâ€“Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2005, 23, 7746-7748.	0.8	4
79	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. Pharmacogenomics and Personalized Medicine, 2011, Volume 4, 1-9.	0.4	4
80	The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells. Cancers, 2022, 14, 1851.	1.7	4
81	Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion. Oncologist, 2022, 27, 7-12.	1.9	3
82	Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine, 2009, 360, 2368-9; author reply 2369-70.	13.9	3
83	Molecular biology of renal-cell carcinoma. European Journal of Cancer, Supplement, 2008, 6, 30-34.	2.2	2
84	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.. , 2009, , .		2
85	Zoledronic acid in early-stage breast cancer. Lancet Oncology, The, 2011, 12, 991.	5.1	1
86	cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?. EBioMedicine, 2020, 57, 102886.	2.7	1
87	Expression and prognostic significance of the EGFR in solid tumors. , 2008, , 210-223.		1
88	Abstract 3581: Characterization of human breast cancer cells with acquired resistance to the EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib. , 2011, , .		1
89	Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment.. Journal of Clinical Oncology, 2010, 28, 10602-10602.	0.8	1
90	35LBA Zoledronic acid affects the ability of mesenchymal stem cells to sustain breast cancer progression. European Journal of Cancer, Supplement, 2009, 7, 17.	2.2	0

#	Article	IF	Citations
91	23 ZOLEDRONIC ACID BLOCKS THE INTERACTION BETWEEN MESENCHYMAL STEM CELLS AND BREAST CANCER CELLS. Cancer Treatment Reviews, 2010, 36, S101-S102.	3.4	0
92	Breast and Colon Carcinomas: Detection with Plasma CRIPTO-1. , 2008, , 189-202.		0
93	Signal Transduction Inhibitors in the Treatment of Breast Cancer. , 2009, , 177-201.		0